Clin2
NCT06468215Possibly a fitRecruiting

Fertility-sparing treatment for early stage 2 endometrial cancer

Carcinoma, EndometrioidFertility Preservation

Part of Blood & lymphatic, Cancer, Hormones & metabolism, Immune system & allergy, Women’s health & pregnancy clinical trials.

This study tests a way to treat early-stage endometrial cancer without removing the uterus, so you can still have a chance to carry a pregnancy. It’s for women under 45 with a grade 2 tumor that hasn’t grown into the womb muscle.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
16 people
Ages
Up to 45 years
Study type
Interventional

Who can take part

  • You have a specific type of cancer called endometrioid adenocarcinoma, Grade 2.
  • The cancer is only in the lining of your womb (uterus) and hasn't spread into the muscle.
  • You are under 45 years old.
  • You want to keep the option to have children in the future.
  • You are willing to sign a form agreeing to try this treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05945407Recruiting
Fertility-sparing treatment for early endometrial cancer

This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.

Beijing, Beijing Municipality
NCT07077876Recruiting
Endometrial cancer and hyperplasia with conservative treatment

This study looks at women with endometrial adenocarcinoma or atypical hyperplasia who had conservative treatment instead of radical surgery. It aims to check how well the treatment works for both cancer and future pregnancy outcomes.

Roma
NCT06549855Recruiting
PD-1 inhibitor plus progesterone for fertility preservation in MMRd endometrial cancer

This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.

Beijing, Beijing Municipality
NCT07714070Not yet recruiting· Phase 2
Orlistat plus progestin for fertility-sparing treatment of early endometrial cancer or atypical hyperplasia

This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.

Beijing, Beijing Municipality
NCT05647109Recruiting
Test tumor-like cell clusters to predict progesterone response

This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.

Beijing, Beijing Municipality
NCT06942377Not yet recruiting· Phase 2
Amlodipine for early-stage endometrial cancer in women under 45

This study tests whether a common blood pressure medication called amlodipine can help treat early-stage endometrial cancer in younger women who want to preserve their fertility. It may be an alternative to hormone therapy, with fewer side effects.

Beijing, Beijing Municipality

Hear when a new Fertility Preservation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.